|
![](/sns/images/shim.gif) |
Registry of Lobbyists - Awalt D Sean
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
Registration Number | Status | | 3177 | Active | | Initial registration date | Last date of any changes | 8-July-2024 | 8-July-2024 |
|
Lobbyist's Last Name Sean |
Lobbyist's First Name Awalt |
Middle Initial D |
|
Business Address of Lobbyist 15 Dewhurst Drive |
City Dartmouth |
Province/State NS |
Country CA |
Postal/Zip Code B2W 2H3 |
Telephone 902-401-9032 |
Fax |
|
Business or Firm Name for Lobbyist (if applicable) AbbVie |
Registry of Joint Stock Companies Number 3287760 |
Business Address of Lobbyist's Business or Firm 8401 Rte Transcanadienne |
City Saint-Laurent |
Province/State PQ |
Country CA |
Postal/Zip Code H4S 1Z1 |
Telephone (514) 906-9700 |
Fax |
|
No other beneficiaries of lobbying activities
|
|
|
Description of Employer's Business: AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca. |
|
|
|
Description |
|
AbbVie Corporation engages the Nova Scotia government to advocate for policies that support timely access to AbbVie’s innovative medicines for appropriate patients More specifically, we engage with government to:
• Advocate for the value of innovative pharmaceuticals in improving patient outcomes and overall savings to the healthcare system, as well as advancing health security and economic growth.
• Identify partnership opportunities with the Government of Nova Scotia, Regional Health Authorities, Nova Scotia Health Innovation Hub, Cancer Care Nova Scotia, and Universities in clinical research on new and existing treatments and therapies, and the generation of real-world evidence.
• Help support health system improvements and healthcare outcomes.
• Advocate for pharmaceutical pricing and reimbursement policies that reflect the value of new medicines to patients and the health care system.
|
View
|
|
|
|
No funding from any government or agency
|
No private funding related to lobbying activities
|
|
|
|